Biogen, Incorporated

Biogen Idec Ma Inc.

Aleta Biotherapeutics Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Minnesota

Biogen Ma Inc.

Biogen Idec, Inc.

Celgene Car LLC

Celgene Avilomics Research, Inc.

Roy R Lobb

Paul David Rennert

Philip Ronald Tempest

Catherine A Hession

Frank J Carr

Susan E Goelz

Philip Gotwals

Victor E Kotelianski

Linda C Burkly

Christopher D Benjamin

Margaret D Rosa

Laurelee Osborn

Antonin De Fougerolles

Arthur F Kluge

Deqiang Niu

Russell Colyn Petter

Shomir Ghosh

Juswinder Singh

Steven P Adams

Lixin Qiao

Zhendong Zhu

Antonin DeFougerolles

John T Schiller

Benjamin Joseph Hackel

Jane K Relton

Victor Koteliansky

Justin Klesmith

Eric Whalley

Victor E Koteliansky

CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.

CD19 variants

Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.

Compositions and methods for treatment of cancer

Some embodiments of the present disclosure are directed to methods that include delivering to a subject a nucleic acid encoding an antigen, wherein the nucleic acid is delivered via a tumor-selective vehicle or via intratumoral injection, and delivering to the subject an immune cell expressing a receptor that binds to the antigen.

Targeted cancer therapy

The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.

Compositions and methods for tumor transduction

The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.

Protein kinase conjugates and inhibitors

A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.

Method for the treatment of inflammatory disorders

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Recombinant anti-VLA4 antibody molecules

Growing community of inventors

Westwood, MA, United States of America

Roy R Lobb